New blood thinner may improve dialysis outcomes in sepsis patients

NCT ID NCT07518303

Not yet recruiting Disease control Sponsor: Jianfeng Xie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two blood thinners used during continuous dialysis in adults with sepsis and acute kidney injury. About 1,162 participants will receive either nafamostat mesylate or standard citrate anticoagulation. The main goal is to see which approach reduces death, ongoing dialysis need, or persistent kidney problems within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nafamostat mesylate
What this could lead to: If nafamostat works better than citrate, it could reduce death, kidney failure, or the need for ongoing dialysis in sepsis patients.
What could go wrong: This is a phase 4 trial, but results may not apply to all patients. Nafamostat could cause bleeding or other side effects, and the benefit over citrate is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) SEPSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.